Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus CORTIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus CORTIFOAM.
ACTICORT vs CORTIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Category C
Category C
Corticosteroid
Corticosteroid